About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

TLCR Chinese Edition more

免疫治疗是晚期非小细胞肺癌去化疗的关键,或还是未到时候?

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)改变了缺乏驱动基因突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗... More >>

晚期或转移性非小细胞肺癌一线免疫治疗中,肿瘤细胞PD-L1表达的阈值究竟在哪

对于晚期或转移性非小细胞肺癌(non-small cell lung cancer,NSCLC),一线免疫治疗对部分患者来说,可以获得比单纯化疗更好的总生存率获益。 More >>

KEYNOTE-042研究:降低帕博利珠单抗单药一线治疗的PD-L1阈值是个好主意吗?

在针对程序性死亡1(programmed death 1,PD-1)或程序性死亡配体1(programmed death ligand 1,PD-L1)的抑制性抗体出现之前,晚期/转移性非小细胞肺癌(... More >>

Original Article

Immunohistochemistry identifies E-cadherin, N-cadherin and focal adhesion kinase (FAK) as predictors of stage I non-small cell lung carcinoma spread through the air spaces (STAS), and the combinations as prognostic factors
Yunchang Meng, Yimin Wang, Leilei Liu, Ranpu Wu, Qingfeng Zhang, Zhangxuan Chen, Yang Yao, Xinjing Li, Yanzhuo Gong, Huijuan Li, Zhaofeng Wang, Hongbing Liu
PD-L1 expression from surgically resected lung tumors predictive of early progression in patients previously treated with targeted therapy for initially unresectable non-small cell lung cancer
Jeong Uk Lim, Hye Seon Kang, Mi Hyoung Moon, Chang Dong Yeo, Young Jo Sa, Tae-Jung Kim, Deog Gon Cho, Seok Whan Moon, Kyung Soo Kim
Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)
Stanislav Fridland, Hye Sung Kim, Young Kwang Chae
Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data
Gabriela Krakorova, Petr Domecky, Jiri Blazek, Milos Pesek, Ondrej Venclicek, Libor Havel†, Michal Hrnciarik, Jana Krejci, Andrea Mullerova, Miloslav Marel, Jaroslav Duba, Martin Svaton
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers
Mariaenrica Tinè, Federica Pezzuto, Manuela Orlandi, Anna Caliò, Stefano Marletta, Tommaso Bondavalli, Diego Giongo, Daniela Reghellin, Ilaria Posenato, Maria Santacatterina, Andrea Menin, Patrick Karl Welte, Francesca Baciorri, Diana Sacchi, Cosimo Catino, Lorenzo Nicolè, Gabriele Foltran, Alessandra D’Urso, Nicla Orzes, Giulia Andreotti, Patrizia Bartolotta, Dario Gregori, Giulia Pasello, Federico Rea, Fiorella Calabrese
Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study
Yang Du, Xiao-Yan Liu, Xiao-Yan Si, Xiao-Tong Zhang, Jing-Ya Zhou, Yi Wang, Min-Jiang Chen, Li Zhang
Lymph node dissection of station 8 improves the survival of T≤3 cmN0M0 lung adenocarcinoma patients
Tengyong Wang, Zihuai Wang, Hui Jie, Chengwu Liu, Shiyou Wei, Hu Liao, Jiandong Mei, Qiang Pu, Lunxu Liu
Association between thymus density loss and efficacy in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Yi Li, Bingxin Gong, Jie Lou, Yusheng Guo, Bo Liang, Weiwei Liu, Ziang You, Chao Chen, Bin Chai, Shanshan Jiang, Hongyong Zhang, Feng Pan, Lian Yang, Guofeng Zhou
Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Yuchen Huang, Wananqi Ma, Dongsheng Wu, Mengyuan Lyu, Quan Zheng, Tengyong Wang, Jian Zhou, Chengwu Liu
Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study
Kazuhito Misawa, Kageaki Watanabe, Masahiro Seike, Yukio Hosomi
Evaluating three-dimensional lung reconstructions for thoracoscopic lung resections using open-source software: a pilot study
Iris E. W. G. Laven, Vincent P. S. Oosterhoff, Aimée J. P. M. Franssen, Lori M. van Roozendaal, Karel W. E. Hulsewé, Yvonne L. J. Vissers, Erik R. de Loos
Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?
Chaoqiang Deng, Chenyu Jiang, Xiangyi Ma, Fangqiu Fu, Shengping Wang, Yuan Li, Yang Zhang, Haiquan Chen
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
Ruchira V. Mahashabde, Sajjad A. Bhatti, Bradley C. Martin, Jacob T. Painter, Analiz Rodriguez, Jun Ying, Chenghui Li
Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study
Raphael Bodensohn, Anna Kolorz, Jonas Reis, Simone Werner, Robert Forbrig, Sylvia Garny, Julian Taugner, Chiara de Colle, Claus Belka, Farkhad Manapov, Louisa von Baumgarten, Maximilian Niyazi
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
Mau Ern Poh, Sivasubramaniam Balakrishnan, Sin Nee Tan, Muhammad Adil Zainal Abidin, Chong Kin Liam, Jiunn Liang Tan, Yong Kek Pang, Arvindran Alaga, Lye Mun Tho, Soon Hin How
PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis
Rafael Parra-Medina, Juan Pablo Castañeda-González, Luisa Montoya, María Paula Gómez-Gómez, Daniel Clavijo Cabezas, Merideidy Plazas Vargas
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study
Haohua Jiang, Yujing Li, Yanan Wang, Benkun Zou, Ya Chen, Yanwei Zhang, Hatim Husain, Fabien Forest, Fangfei Qian, Lele Zhang, Chao Zhou, Hongyu Liu, Danni Wang, Wei Zhang, Jun Lu, Baohui Han
Sublobar resection for lung adenocarcinoma less than 2 cm containing solid or micropapillary components radiologically presented as consolidation-to-tumor ratio (CTR) ≤0.25 [ground-glass opacity (GGO)]
Mingyang Zhu, Yuanyuan Xu, Jiazheng Huang, Yaxian Yao, Davide Tosi, Terumoto Koike, Nestor R. Villamizar, Ziang Wang, Feng Mao, Qingquan Luo, Qiang Tan
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations
Xiaoyu Ji, Rongrong Jiang, Tao Liu, Mariano Provencio, Sang Chul Lee, Qiong Zhan, Xinli Zhou
Tumor cavitation in patients with non-small-cell lung cancer receiving anti-angiogenic therapy with apatinib
Qian Cai, Kui Hu, Shuang Dong, Xiaoyu Li, Sheng Hu, Wenyou Deng, Wulin Ou
Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk
Yifan Liu, Xinxin Ying, Yao Li, Xingyu Zhu, Wangwei Jing, Xiaohong Wang, Zhengfu He
miR-16-5p specifically inhibits IFN-γ-regulated memory T helper cell differentiation in malignant pleural effusion of non-small cell lung cancer
Yi Sun, Xiaofen Qiu, Dalei Zhou, Sara Ricciardi, Shuichi Shinohara, Jiangjun Ma

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Bryan A. Chan, Brett G.M. Hughes
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Global trends of lung cancer mortality and smoking prevalence
Farhad Islami, Lindsey A. Torre, Ahmedin Jemal
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid, Asim Amin

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song
Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen
The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden
The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices
Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto, Fumihiro Tanaka
Prognostic markers in lung cancer: is it ready for prime time?
Chang-Qi Zhu, Ming-Sound Tsao
Potential biomarkers for lung cancer screening
Gabriella Sozzi, Mattia Boeri
Particle therapy in non-small cell lung cancer
Zhongxing Liao, Charles B. Simone II
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Suchit H. Patel, Andreas Rimner, Roger B. Cohen
Intraoperative near-infrared imaging of mesothelioma
Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal
BAP1, a tumor suppressor gene driving malignant mesothelioma
Mitchell Cheung, Joseph R. Testa
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang
Immunotherapy for malignant pleural mesothelioma: current status and future directions
Jordan Dozier, Hua Zheng, Prasad S. Adusumilli
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
Linda O’Flaherty, Harriet Wikman, Klaus Pantel
Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?
Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace
Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer
Sumitra Mohan, Francesca Chemi, Ged Brady
Biophysical technologies for understanding circulating tumor cell biology and metastasis
Derrick W. Su, Jorge Nieva
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer
Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer
Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung
Yoon Jin Cha, Hyo Sup Shim
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.